vs
COMPASS MINERALS INTERNATIONAL INC（CMP）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
COMPASS MINERALS INTERNATIONAL INC的季度营收约是Prestige Consumer Healthcare Inc.的1.4倍（$396.1M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 4.7%，领先11.8%），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $-59.8M），过去两年COMPASS MINERALS INTERNATIONAL INC的营收复合增速更高（4.3% vs 1.2%）
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
CMP vs PBH — 直观对比
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $396.1M | $283.4M |
| 净利润 | $18.6M | $46.7M |
| 毛利率 | 16.0% | 55.5% |
| 营业利润率 | 9.2% | 29.1% |
| 净利率 | 4.7% | 16.5% |
| 营收同比 | 28.9% | -2.4% |
| 净利润同比 | 178.8% | -23.5% |
| 每股收益（稀释后） | $0.43 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $396.1M | $283.4M | ||
| Q3 25 | $227.5M | $274.1M | ||
| Q2 25 | $214.6M | $249.5M | ||
| Q1 25 | $494.6M | $296.5M | ||
| Q4 24 | $307.2M | $290.3M | ||
| Q3 24 | $208.8M | $283.8M | ||
| Q2 24 | $202.9M | $267.1M | ||
| Q1 24 | $364.0M | $277.0M |
| Q4 25 | $18.6M | $46.7M | ||
| Q3 25 | $-7.2M | $42.2M | ||
| Q2 25 | $-17.0M | $47.5M | ||
| Q1 25 | $-32.0M | $50.1M | ||
| Q4 24 | $-23.6M | $61.0M | ||
| Q3 24 | $-48.3M | $54.4M | ||
| Q2 24 | $-43.6M | $49.1M | ||
| Q1 24 | $-38.9M | $49.5M |
| Q4 25 | 16.0% | 55.5% | ||
| Q3 25 | 16.9% | 55.3% | ||
| Q2 25 | 19.2% | 56.2% | ||
| Q1 25 | 15.5% | 57.3% | ||
| Q4 24 | 11.2% | 55.5% | ||
| Q3 24 | 9.3% | 55.5% | ||
| Q2 24 | 16.1% | 54.7% | ||
| Q1 24 | 19.7% | 54.8% |
| Q4 25 | 9.2% | 29.1% | ||
| Q3 25 | 5.3% | 29.1% | ||
| Q2 25 | 7.4% | 28.8% | ||
| Q1 25 | -0.6% | 29.8% | ||
| Q4 24 | 0.2% | 31.7% | ||
| Q3 24 | -14.3% | 29.7% | ||
| Q2 24 | 2.9% | 27.0% | ||
| Q1 24 | -10.8% | 29.7% |
| Q4 25 | 4.7% | 16.5% | ||
| Q3 25 | -3.2% | 15.4% | ||
| Q2 25 | -7.9% | 19.0% | ||
| Q1 25 | -6.5% | 16.9% | ||
| Q4 24 | -7.7% | 21.0% | ||
| Q3 24 | -23.1% | 19.2% | ||
| Q2 24 | -21.5% | 18.4% | ||
| Q1 24 | -10.7% | 17.9% |
| Q4 25 | $0.43 | $0.97 | ||
| Q3 25 | — | $0.86 | ||
| Q2 25 | $-0.41 | $0.95 | ||
| Q1 25 | $-0.77 | $1.00 | ||
| Q4 24 | $-0.57 | $1.22 | ||
| Q3 24 | $-1.17 | $1.09 | ||
| Q2 24 | $-1.05 | $0.98 | ||
| Q1 24 | $-0.94 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.7M | $62.4M |
| 总债务越低越好 | $890.0M | $1.0B |
| 股东权益账面价值 | $260.5M | $1.8B |
| 总资产 | $1.5B | $3.5B |
| 负债/权益比越低杠杆越低 | 3.42× | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $46.7M | $62.4M | ||
| Q3 25 | $59.7M | $119.1M | ||
| Q2 25 | $79.4M | $139.5M | ||
| Q1 25 | $49.5M | $97.9M | ||
| Q4 24 | $45.8M | $50.9M | ||
| Q3 24 | $20.2M | $51.5M | ||
| Q2 24 | $12.8M | $34.3M | ||
| Q1 24 | $38.3M | $46.5M |
| Q4 25 | $890.0M | $1.0B | ||
| Q3 25 | $839.8M | $993.1M | ||
| Q2 25 | $833.4M | $992.7M | ||
| Q1 25 | $807.6M | $992.4M | ||
| Q4 24 | $974.4M | $992.0M | ||
| Q3 24 | $921.2M | $1.1B | ||
| Q2 24 | $875.1M | $1.1B | ||
| Q1 24 | $877.2M | $1.1B |
| Q4 25 | $260.5M | $1.8B | ||
| Q3 25 | $234.1M | $1.8B | ||
| Q2 25 | $249.8M | $1.9B | ||
| Q1 25 | $236.5M | $1.8B | ||
| Q4 24 | $263.0M | $1.8B | ||
| Q3 24 | $316.6M | $1.7B | ||
| Q2 24 | $352.1M | $1.7B | ||
| Q1 24 | $400.4M | $1.7B |
| Q4 25 | $1.5B | $3.5B | ||
| Q3 25 | $1.5B | $3.4B | ||
| Q2 25 | $1.5B | $3.4B | ||
| Q1 25 | $1.5B | $3.4B | ||
| Q4 24 | $1.7B | $3.3B | ||
| Q3 24 | $1.6B | $3.3B | ||
| Q2 24 | $1.6B | $3.3B | ||
| Q1 24 | $1.7B | $3.3B |
| Q4 25 | 3.42× | 0.56× | ||
| Q3 25 | 3.59× | 0.54× | ||
| Q2 25 | 3.34× | 0.54× | ||
| Q1 25 | 3.41× | 0.54× | ||
| Q4 24 | 3.70× | 0.55× | ||
| Q3 24 | 2.91× | 0.61× | ||
| Q2 24 | 2.49× | 0.65× | ||
| Q1 24 | 2.19× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.0M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $75.3M |
| 自由现金流率自由现金流/营收 | -15.1% | 26.6% |
| 资本支出强度资本支出/营收 | 5.8% | 1.1% |
| 现金转化率经营现金流/净利润 | -1.99× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $94.1M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-37.0M | $78.3M | ||
| Q3 25 | $-6.9M | $57.5M | ||
| Q2 25 | $21.8M | $79.0M | ||
| Q1 25 | $186.9M | $61.8M | ||
| Q4 24 | $-4.1M | $65.1M | ||
| Q3 24 | $-12.7M | $69.8M | ||
| Q2 24 | $-6.8M | $54.8M | ||
| Q1 24 | $86.2M | $66.9M |
| Q4 25 | $-59.8M | $75.3M | ||
| Q3 25 | $-22.8M | $55.4M | ||
| Q2 25 | $3.8M | $78.2M | ||
| Q1 25 | $172.9M | $58.4M | ||
| Q4 24 | $-25.9M | $63.5M | ||
| Q3 24 | $-33.6M | $67.8M | ||
| Q2 24 | $-21.5M | $53.6M | ||
| Q1 24 | $56.2M | $63.8M |
| Q4 25 | -15.1% | 26.6% | ||
| Q3 25 | -10.0% | 20.2% | ||
| Q2 25 | 1.8% | 31.3% | ||
| Q1 25 | 35.0% | 19.7% | ||
| Q4 24 | -8.4% | 21.9% | ||
| Q3 24 | -16.1% | 23.9% | ||
| Q2 24 | -10.6% | 20.1% | ||
| Q1 24 | 15.4% | 23.0% |
| Q4 25 | 5.8% | 1.1% | ||
| Q3 25 | 7.0% | 0.8% | ||
| Q2 25 | 8.4% | 0.3% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | 7.1% | 0.5% | ||
| Q3 24 | 10.0% | 0.7% | ||
| Q2 24 | 7.2% | 0.4% | ||
| Q1 24 | 8.2% | 1.1% |
| Q4 25 | -1.99× | 1.68× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
